We are live on ! Find out more
QUSVM

Qiming U.S. Ventures Management Portfolio holdings

AUM $55.6M
1-Year Est. Return 98.09%
This Fund
S&P 500
This Quarter Est. Return
+7.71%
1 Year Est. Return
+98.09%
3 Year Est. Return
+1,484.17%
5 Year Est. Return
10 Year Est. Return
AUM
$23.6M
AUM Growth
+$513K
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TRML
1
DELISTED
Tourmaline Bio
TRML
$11.9M 50.22%
741,691
JSPR icon
2
Jasper Therapeutics
JSPR
$22.9M
$5.16M 21.83%
928,964
KRRO icon
3
Korro Bio
KRRO
$153M
$4.6M 19.47%
368,085
VTYX
4
DELISTED
Ventyx Biosciences
VTYX
$882K 3.74%
412,225
HLVX
5
DELISTED
HilleVax
HLVX
$742K 3.14%
372,615
KZR
6
DELISTED
Kezar Life Sciences
KZR
$380K 1.61%
82,871

Similar funds

Qiming U.S. Ventures Management's Q2 2025 Portfolio in Review

As of Q2 2025, Qiming U.S. Ventures Management held 6 positions worth $23.6M, up 2.2% from $23.1M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Qiming U.S. Ventures Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Qiming U.S. Ventures Management's ten largest holdings make up 100% of its $23.6M portfolio in Q2 2025.
  • Qiming U.S. Ventures Management opened 0 new positions and closed 0 in Q2 2025.
  • Qiming U.S. Ventures Management's portfolio value rose 2.2% quarter-over-quarter to $23.6M.

Based on Qiming U.S. Ventures Management's 13F filing for Q2 2025, filed 14 Aug 2025.